Study of immune changes in brain lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at the immune system and metabolism of people with primary central nervous system lymphoma (a type of brain cancer) to find differences that might help with future treatments. It does not test a new drug, but collects samples and medical information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with primary central nervous system lymphoma (brain lymphoma).
- You cannot have received any cancer treatment yet for this diagnosis.
- You must be able to provide MRI or CT images and pathology reports.
- You cannot have another type of cancer, a severe infection, or a serious organ condition like kidney or liver failure.
- You must be willing to sign a consent form and give blood or tissue samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood, cerebrospinal fluid, and tumor tissue samples over time from people with suspected or confirmed primary central nervous system lymphoma (PCNSL) in China. The goal is to build a large biobank to better understand the disease and improve future diagnosis and treatment.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.